Skye Bioscience, Inc. Common Stock - Asset Resilience Ratio
Skye Bioscience, Inc. Common Stock (SKYE) has an Asset Resilience Ratio of 18.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Skye Bioscience, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Skye Bioscience, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Skye Bioscience, Inc. Common Stock balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Skye Bioscience, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SKYE total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00 Million | 18.09% |
| Total Liquid Assets | $2.00 Million | 18.09% |
Asset Resilience Insights
- Good Liquidity Position: Skye Bioscience, Inc. Common Stock maintains a healthy 18.09% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Skye Bioscience, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Skye Bioscience, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Skye Bioscience, Inc. Common Stock (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Skye Bioscience, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.12% | $19.85 Million | $28.31 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $72.76 Million | -- |
| 2023-12-31 | -76.05% | $-9.08 Million | $11.94 Million | -77.11pp |
| 2015-12-31 | 1.07% | $37.50K | $3.51 Million | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more